MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326877 | Name: Aminaphthone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aminaphthone, also known as Capilarema, is a drug used for the treatment of capillary disorders. Aminaftone inhibits ET-1 production in cell cultures by interfering with transcription of the PPET-1 gene. Aminaftone reduced plasma concentration of ET-1 and seemed to reduce right heart hypertrophy and the wall thickness of the pulmonary arteries at the highest dose. Aminaftone may represent a novel treatment strategy of pulmonary hypertension.

Chemical Structure

Aminaphthone
Aminaphthone
CAS#14748-94-8

Theoretical Analysis

MedKoo Cat#: 326877

Name: Aminaphthone

CAS#: 14748-94-8

Chemical Formula: C18H15NO4

Exact Mass: 309.1001

Molecular Weight: 309.32

Elemental Analysis: C, 69.89; H, 4.89; N, 4.53; O, 20.69

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Aminaphthone, Capilarema.
IUPAC/Chemical Name
1,4-Dihydroxy-3-methyl-2-naphthyl 4-aminobenzoate
InChi Key
YLMPBJUYFTWHKJ-UHFFFAOYSA-N
InChi Code
InChI=1S/C18H15NO4/c1-10-15(20)13-4-2-3-5-14(13)16(21)17(10)23-18(22)11-6-8-12(19)9-7-11/h2-9,20-21H,19H2,1H3
SMILES Code
O=C(OC1=C(C)C(O)=C2C=CC=CC2=C1O)C3=CC=C(N)C=C3
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 309.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capellà D, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016 Apr 6;4:CD003229. doi: 10.1002/14651858.CD003229.pub3. Review. PubMed PMID: 27048768. 2: Bentivegna E, Citarrella E, Vivaldi R, De Luca D, Maira GG, Casuccio A, Di Carlo P. Leg ulcer and osteomyelitis due to methicillin-susceptible Staphylococcus aureus infection after fracture repair treatment: a case highlighting the potential role of prostaglandin E₁ vasodilator. Infez Med. 2015 Mar;23(1):69-73. PubMed PMID: 25819055. 3: Romano C, Tamburella C, Costa M, Messina M, Fassari AL, Bertini M. Aminaphtone therapy in patients with type 1 diabetes and albuminuria: a case report. J Med Case Rep. 2014 Dec 19;8:443. doi: 10.1186/1752-1947-8-443. PubMed PMID: 25524258; PubMed Central PMCID: PMC4320529. 4: Pereira de Godoy JM, Macedo Paizan ML. Aminaphtone in the control of gingival bleeding in children. Drug Des Devel Ther. 2014 Sep 10;8:1331-4. doi: 10.2147/DDDT.S65610. eCollection 2014. PubMed PMID: 25246774; PubMed Central PMCID: PMC4166210. 5: Frullini A, Da Pozzo E, Felice F, Burchielli S, Martini C, Di Stefano R. Prevention of excessive endothelin-1 release in sclerotherapy: in vitro and in vivo studies. Dermatol Surg. 2014 Jul;40(7):769-75. doi: 10.1111/dsu.0000000000000038. PubMed PMID: 25111350. 6: Belczak SQ, Sincos IR, Campos W, Beserra J, Nering G, Aun R. Veno-active drugs for chronic venous disease: A randomized, double-blind, placebo-controlled parallel-design trial. Phlebology. 2014 Aug;29(7):454-60. doi: 10.1177/0268355513489550. Epub 2013 May 16. PubMed PMID: 23761871. 7: Salvatore S, Bertini M, Vingolo EM. Aminaphtone in the treatment of pseudophakic cystoid macular edema: a case report. Clin Ter. 2011;162(5):e135-7. PubMed PMID: 22041810. 8: de Godoy JM, de Godoy Mde F. Evaluation of the prevalence of concomitant idiopathic cyclic edema and cellulite. Int J Med Sci. 2011;8(6):453-5. Epub 2011 Aug 2. PubMed PMID: 21850194; PubMed Central PMCID: PMC3156991. 9: Zambelli V, Santaniello A, Fumagalli F, Masson S, Scorza R, Beretta L, Latini R. Efficacy of aminaftone in a rat model of monocrotaline-induced pulmonary hypertension. Eur J Pharmacol. 2011 Sep 30;667(1-3):287-91. doi: 10.1016/j.ejphar.2011.05.060. Epub 2011 May 30. PubMed PMID: 21641342. 10: Scorza R, Santaniello A, Salazar G, Lenna S, Colombo G, Turcatti F, Beretta L. Aminaftone, a derivative of 4-aminobenzoic acid, downregulates endothelin-1 production in ECV304 Cells: an in vitro Study. Drugs R D. 2008;9(4):251-7. PubMed PMID: 18588356. 11: Scorza R, Santaniello A, Salazar G, Lenna S, Della Bella S, Antonioli R, Toussoun K, Beretta L. Effects of aminaftone 75 mg TID on soluble adhesion molecules: a 12-week, randomized, open-label pilot study in patients with systemic sclerosis. Clin Ther. 2008 May;30(5):924-9. doi: 10.1016/j.clinthera.2008.05.009. PubMed PMID: 18555939. 12: Pereira de Godoy JM. Aminaphtone in idiopathic cyclic oedema syndrome. Phlebology. 2008;23(3):118-9. doi: 10.1258/phleb.2007.007054. PubMed PMID: 18467619. 13: Bambagiotti-Alberti M, Bartolucci G, Bruni B, Coran S, Di Vaira M. 3-Methyl-1,4-dioxo-1,4-dihydro-naphthalen-2-yl 4-amino-benzoate. Acta Crystallogr Sect E Struct Rep Online. 2008 Mar 14;64(Pt 4):o718. doi: 10.1107/S1600536808005308. PubMed PMID: 21202108; PubMed Central PMCID: PMC2961024. 14: Martinez MJ, Bonfill X, Moreno RM, Vargas E, Capellà D. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003229. Review. Update in: Cochrane Database Syst Rev. 2016;4:CD003229. PubMed PMID: 16034893. 15: De Anna D, Mari F, Intini S, Gasbarro V, Sortini A, Pozza E, Marzola R, Taddeo U, Bresadola F, Donini I. [Effects of therapy with aminaftone on chronic venous and lymphatic stasis]. Minerva Cardioangiol. 1989 May;37(5):251-4. Italian. PubMed PMID: 2789348. 16: Consoli V, Alfieri P, Betti E. [Evaluation of the activity of aminaftone as coadjuvant treatment in various traumatic injuries]. Clin Ter. 1985 Jul 31;114(2):111-5. Italian. PubMed PMID: 3876909. 17: Doni A, Mondaini F, Somigli M, Comparini L, Gavazzi M, Ventimiglia V. [Modification of primary hemostasis and capillary fragility induced by aminaftone in chronic renal insufficiency]. Clin Ter. 1983 Oct 15;107(1):45-50. Italian. PubMed PMID: 6606524. 18: Bonanni G, Ciccariello M, Fischetti G, Gigli M, Fava A, Temperini U, Paradiso Galatioto G. [Review of 1000 hematuric patients in the hospitals in Rome, with special reference to the methods of diagnosis and therapy]. Clin Ter. 1983 Feb 28;104(4):305-17. Italian. PubMed PMID: 6602685. 19: Chimenti S, Faina P. [Therapeutic activity of aminaphthone in purpuric disorders]. Clin Ter. 1978 Mar 15;84(5):501-8. Italian. PubMed PMID: 306333.